[Cerebrospinal toxoplasmosis: detection, clinical course and therapy].
With modern techniques (membrane marking by indirect immunofluorescence and identification by morphological criteria) Toxoplasma gondii can be reliably identified in the CSF. Identification of the causative agent confirms the diagnosis of toxoplasmosis of the meninges, the central nervous system and the nerve roots. Toxoplasma encephalomyelitis associated with meningoradiculitis has hitherto only rarely been described. Our own cases afford evidence of the fact that even in the most typical cases of multiple sclerosis this possibility must be considered. Fansidar (a combination of an ultralong-acting sulfonamide with pyrimethamine combined with spiramycine is recommended as the treatment of choice.
D000293:Adolescent; D000328:Adult; D000906:Antibodies; D000941:Antigens / Q000134:cerebrospinal fluid; D002555:Cerebrospinal Fluid / Q000469:parasitology; D004679:Encephalomyelitis / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000627:therapeutic use; D014122:Toxoplasma / Q000276:immunology / Q000302:isolation & purification*; D014123:Toxoplasmosis / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000276:immunology
D000906:Antibodies; D000941:Antigens; D007933:Leucomycins; D013449:Sulfonamides
Zerebrospinale Toxoplasmose: Aktuelles zum Erregernachweis, der Klinik und Therapie.